Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly
SGEN [NASD]
Seattle Genetics Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-0.49 Insider Own1.50% Shs Outstand120.46M Perf Week-4.08%
Market Cap3.88B Forward P/E- EPS next Y-0.61 Insider Trans-4.09% Shs Float119.73M Perf Month-12.26%
Income-57.70M PEG- EPS next Q-0.19 Inst Own- Short Float14.74% Perf Quarter-2.69%
Sales219.90M P/S17.64 EPS this Y65.70% Inst Trans1.89% Short Ratio22.60 Perf Half Y37.08%
Book/sh1.94 P/B16.60 EPS next Y25.60% ROA-13.00% Target Price32.42 Perf Year27.63%
Cash/sh2.86 P/C11.27 EPS next 5Y0.00% ROE-25.70% 52W Range21.05 - 39.00 Perf YTD38.97%
Dividend- P/FCF- EPS past 5Y10.50% ROI-25.30% 52W High-17.44% Beta1.02
Dividend %- Quick Ratio4.50 Sales past 5Y56.60% Gross Margin93.40% 52W Low52.97% ATR1.38
Employees538 Current Ratio4.80 Sales Q/Q18.90% Oper. Margin-26.40% RSI (14)38.49 Volatility3.98% 4.14%
OptionableYes Debt/Eq0.00 EPS Q/Q-27.30% Profit Margin-26.30% Rel Volume0.61 Prev Close31.98
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume780.71K Price32.20
Recom2.70 SMA20-5.90% SMA50-9.61% SMA2008.78% Volume473,000 Change0.69%
22-Apr-13Reiterated RBC Capital Mkts Outperform $32 → $40
13-Feb-13Downgrade Needham Buy → Hold
08-Nov-12Downgrade Cantor Fitzgerald Hold → Sell $30 → $20
07-Sep-12Downgrade Oppenheimer Outperform → Perform $28 → $27
21-Aug-12Initiated Cantor Fitzgerald Buy $30
08-Jun-12Reiterated Needham Buy $20 → $25
11-Nov-11Initiated Needham Buy $20
05-Oct-11Initiated Summer Street Research Sell
05-Aug-11Reiterated UBS Neutral $21 → $16
15-Jul-11Reiterated Oppenheimer Outperform $21 → $24
17-Jun-11Reiterated Oppenheimer Outperform $18 → $21
06-May-11Reiterated Needham Buy $18 → $22
09-Mar-11Initiated BioLogic Equity Research Sell
21-Jan-11Reiterated Oppenheimer Outperform $20 → $18
06-Jan-11Reiterated ThinkEquity Buy $19 → $20
02-Nov-10Downgrade Canaccord Genuity Buy → Sell $16 → $10
01-Nov-10Downgrade Brean Murray Hold → Sell $11
12-Oct-10Reiterated RBC Capital Mkts Outperform $16 → $20
08-Oct-10Reiterated ThinkEquity Buy $16 → $19
28-Sep-10Upgrade ThinkEquity Hold → Buy $12 → $16
17-Jun-13 09:00AM  Immunotherapy: Four Companies on the Verge of Cancer-Treatment Breakthroughs at Minyanville
15-Jun-13 12:17PM  A Trio of Cancer Immunotherapy Innovators at Motley Fool
11-Jun-13 06:15PM  SGEN Starts Adcetris Phase I/II Study Zacks
10:17AM  Acadia Pharmaceuticals Soars On Hedge Fund Investment at Motley Fool
10-Jun-13 09:00AM  Seattle Genetics Announces Initiation of Phase 1/2 Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Bendamustine for Hodgkin Lymphoma Patients after Initial Relapse Business Wire
05-Jun-13 06:32AM  3 Pharmaceuticals With Strong Potential at Seeking Alpha
03-Jun-13 03:17PM  MCO, MSFT & SGEN - Outperforming, Cash-Rich Stocks at TheStreet
01:50AM  InPlay: Seattle Genetics highlights ADCETRIS Frontline HL and MTCL clinical development programs and antibody-drug conjugate collaborator data Briefing.com
02-Jun-13 09:00AM  Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting Business Wire
29-May-13 09:00AM  Seattle Genetics to Present at Upcoming Investor Conferences Business Wire
22-May-13 09:45AM  SEATTLE GENETICS INC /WA Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
06:02AM  Hodgkin Lymphoma: The Top Secret Strategy Of Seattle Genetics Revealed at Seeking Alpha
21-May-13 03:30PM  Seattle Genetics Inc. Presents at UBS Global Healthcare Conference, May-21-2013 11:30 AM at Seeking Alpha
19-May-13 06:30PM  Tackling Cancer: Leukemia's Biggest Current and Upcoming Players at Motley Fool
16-May-13 03:39PM  A Portfolio Construction Strategy with an Emphasis on High-Innovation, Breakthrough Biotech and Pharmaceutical Companies Wall Street Transcript
03:30PM  SGEN's Adcetris under FDA Review Zacks
15-May-13 01:04PM  SEATTLE GENETICS INC /WA Financials EDGAR Online Financials
12:31AM  Seattle Genetics' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript) at Seeking Alpha
14-May-13 10:29AM  FDA accepts Seattle Genetics Adcetris application AP
09:03AM  InPlay: Seattle Genetics announces ADCETRIS supplemental BLA accepted for filing by the FDA Briefing.com
09:00AM  Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Supplemental BLA Accepted for Filing by the FDA Business Wire
13-May-13 04:54PM  Companies Invest in Antibodies That Fight Tumors at Motley Fool
11-May-13 06:43PM  These 4 Stocks Saw Trading Price Swings This Past Week Post Earnings at Wall St. Cheat Sheet
09-May-13 09:00AM  Seattle Genetics to Present at Upcoming Investor Conferences Business Wire
04:09AM  The True Value Of Seattle Genetics at Seeking Alpha
08-May-13 10:00AM  Narrower-than-Expected Loss at Seattle Genetics Zacks
09:17AM  SEATTLE GENETICS INC /WA Files SEC form 10-Q, Quarterly Report EDGAR Online
07-May-13 08:40PM  Seattle Genetics Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha
05:07PM  Seattle Genetics Earnings: Heres Why Shares are Up Now at Wall St. Cheat Sheet
04:30PM  Seattle Genetics Earnings Call scheduled for 4:30 pm ET today CCBN
04:19PM  Seattle Genetics Earnings Call scheduled for 4:30 pm ET today CCBN
04:05PM  Seattle Genetics Reports First Quarter 2013 Financial Results Business Wire
01:58PM  Right Time To Buy This Pharmaceutical Company? at Motley Fool
09:16AM  SEATTLE GENETICS INC /WA Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
07:07AM  Q1 2013 Seattle Genetics Earnings Release - After Market Close CCBN
03-May-13 11:43AM  Drug Manufacturers and the FDA Collaborate More Closely for Faster Drug Approval: An Exclusive Interview with an Expert Equity Analyst Reveals Some Top Stock Picks in This Vital Industry Wall Street Transcript
11:17AM  Dr. Jason Kantor, Research Analyst at Credit Suisse Group, Interviews with The Wall Street Transcript: High Success Rates and Significant M&A in the Antibody Space Wall Street Transcript
26-Apr-13 11:50AM  William A. Hartman, President & Chief Executive Officer of Premier Biomedical, Inc. (BIEI), Interviews with The Wall Street Transcript Wall Street Transcript
22-Apr-13 01:58PM  Apple is a Buy and 4 More Analyst Opinions to Know Now at Wall St. Cheat Sheet
19-Apr-13 02:13PM  5 Stocks Poised for Breakouts at TheStreet +5.36%
18-Apr-13 04:08PM  Mega-Hedge Fund Focusing on the Life Sciences at Motley Fool
09:00AM  Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2013 Financial Results on May 7, 2013 Business Wire
17-Apr-13 02:20PM  Tackling Cancer: Non-Hodgkin Lymphoma's Biggest Current & Upcoming Players at Motley Fool
16-Apr-13 06:43PM  Lightning Round: Dollar Tree, Toll Brothers & More at CNBC
10-Apr-13 05:25PM  ADC Data from Seattle Genetics Zacks
09-Apr-13 01:00PM  Seattle Genetics and Collaborators Highlight Multiple Antibody-Drug Conjugate (ADC) Programs and Technology Advances at AACR Business Wire
06-Apr-13 04:16PM  This Biotech Stock Looks Like a Good Investment at Motley Fool
05-Apr-13 04:58PM  Astellas, Ambrx Tie-Up on ADC Zacks
07:55AM  Biotech Stock Mailbag: MannKind, Ariad, Oncolytics Biotech at TheStreet
06:00AM  Cramer's Top Stock Picks: QQQ IMGN SGEN ONXX at TheStreet
04-Apr-13 08:21PM  Cramer's 'Mad Money' Recap: Economists Don't Know Stocks at TheStreet
06:28PM  Cramer: Investing in Future of Cancer Drugs at CNBC
29-Mar-13 07:00AM  Our Outlook for Health-Care Stocks Morningstar
28-Mar-13 05:01PM  Declines From Seattle Genetics Inc. (SGEN) Drive Down Health Care Sector at TheStreet
27-Mar-13 02:28PM  Takeda Files Adcetris in Japan Zacks
26-Mar-13 05:02PM  Seattle Genetics Moves Up In Market Cap Rank, Passing Owens-Illinois at Forbes
19-Mar-13 05:43PM  SGEN Seeks Adcetris Label Expansion Zacks
18-Mar-13 10:02AM  InPlay: Seattle Genetics submits supplemental BLA to FDA for retreatment and extended duration of therapy with ADCETRIS in relapsed hodgkin lymphoma and systemic ALCL Briefing.com
09:02AM  Seattle Genetics submits sBLA to FDA for ADCETRIS theflyonthewall.com
09:00AM  Seattle Genetics Submits Supplemental BLA to FDA for Retreatment and Extended Duration of Therapy with ADCETRIS® (Brentuximab Vedotin) in Relapsed Hodgkin Lymphoma and Systemic ALCL Business Wire
15-Mar-13 06:00PM  What Is This CEO Doing to Earn $450 Per Hour? at Motley Fool
13-Mar-13 05:20PM  Seattle Genetics Inc. Presents at Barclays Global Healthcare Conference, Mar-13-2013 03:15 PM at Seeking Alpha
09:45AM  SanDisk CEO Sells 20K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
11-Mar-13 10:36AM  Cisco Senior VP Sells More Than 47K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
08-Mar-13 05:48PM  Investing in a Cheap Life at Motley Fool
07-Mar-13 03:14PM  Five bullish charts to watch at MarketWatch
05-Mar-13 01:04PM  SEATTLE GENETICS INC /WA Financials EDGAR Online Financials +5.15%
08:20AM  Biotech Industry Soars in 2012 as FDA Drug Approvals Reach a 15-Year High Marketwire
27-Feb-13 04:18PM  SEATTLE GENETICS INC /WA Files SEC form 10-K, Annual Report EDGAR Online
09:05AM  This FDA Approval Is Actually a Big Deal at Motley Fool
09:00AM  Seattle Genetics to Present at Upcoming Investor Conferences Business Wire
26-Feb-13 06:34PM  4 Cancer Treatments On The Way Up at Seeking Alpha
22-Feb-13 04:30PM  Finally Approved! Now, About Those Sales... at Motley Fool
11:07AM  F.D.A. Approves a New Drug for Advanced Breast Cancer at New York Times
10:38AM  Genentech wins FDA approval for 'smart bomb' against breast cancer at bizjournals.com
19-Feb-13 05:04PM  Massachusetts company pays $38 million for Seattle Genetics headquarters at bizjournals.com
18-Feb-13 09:11AM  Anything Can Happen This Year For Celldex at Seeking Alpha
13-Feb-13 01:51PM  Dell Downgraded to Hold and 4 Downgraded Stocks to Watch at Wall St. Cheat Sheet -5.06%
12:39PM  Why Seattle Genetics Dropped at Motley Fool
12:04PM  4 Stocks Pushing The Drugs Industry Lower at TheStreet
09:26AM  SGEN Narrows Loss, Sales Rise Zacks
08:10AM  BRIEF-Seattle Genetics down 3.6 percent in premarket at Reuters
12:02AM  Seattle Genetics' CEO Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha
12-Feb-13 11:12PM  Seattle Genetics downgraded by Needham Briefing.com
06:03PM  Seattle Genetics reports revenue bump with Adcetris at bizjournals.com
05:57PM  Seattle Genetics Earnings: Heres Why Investors are Not Happy Now at Wall St. Cheat Sheet
04:30PM  Seattle Genetics Earnings Call scheduled for 4:30 pm ET today CCBN
04:23PM  SEATTLE GENETICS INC /WA Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
04:17PM  InPlay: Seattle Genetics beats by $0.01, beats on revs Briefing.com
04:05PM  Seattle Genetics Reports Fourth Quarter and Year 2012 Financial Results Business Wire
02:38PM  Five Super Ideas in the Healthcare Sector at Motley Fool
07:36AM  Seattle Genetics Earnings Call scheduled for 4:30 pm ET today CCBN
07:07AM  Q4 2012 Seattle Genetics Earnings Release - After Market Close CCBN
11-Feb-13 12:57PM  5 Stocks Poised to Pop on Bullish Earnings at TheStreet
05:05AM  3 Cutting Edge Cancer Therapies May Target Investor Portfolios To Yield Gains at Seeking Alpha
10-Feb-13 12:02PM  5 Can't-Miss Health-Care Events This Week at Motley Fool
07-Feb-13 04:43PM  SGEN Starts SGN-CD19A Phase I Study Zacks
06-Feb-13 09:00AM  Seattle Genetics Initiates Two Phase I Trials of SGN-CD19A Business Wire
05-Feb-13 03:38PM  Baker Brothers Reports Stakes in InterMune and Repros Therapeutics at Motley Fool
04-Feb-13 05:18PM  Canada Approves Seattle Genetics' Adcetris Zacks
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Food and Drug Administration for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens; and for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The company's ADCETRIS is in Phase III trial for patients with Hodgkin lymphoma at high risk of relapse following ASCT; Phase II retreatment trial for patients with Hodgkin lymphoma or sALCL; Phase II trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas; Phase II CD30-screening and treatment trial for patients with CD30-positive non-lymphoma malignancies; Phase I safety trial in combination with Adriamycin, vinblastine, bleomycin, and dacarbazine, or in combination with AVD for front-line treatment of patients with Hodgkin lymphoma; and Phase I safety trial for the treatment of patients with mature T-cell lymphomas, including sALCL. Its product pipeline also comprises SGN-75, which completed Phase I trial for relapsed or refractory non-Hodgkin lymphoma and renal cell carcinoma; ASG-5ME that is in Phase I trial for treating metastatic pancreatic cancer and castration-resistant prostate cancer; ASG-22ME, which is in Phase I trial for treatment of Nectin-4 -positive solid tumors; and SGN-CD19A for CD19-positive hematologic malignancies. The company has a strategic collaboration with Oxford BioTherapeutics Ltd. to jointly discover antibody-drug conjugates (ADC) for the treatment of cancer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AKKARAJU SRINIVASDirectorJun 14Option Exercise8.385,00041,90018,905Jun 17 07:28 PM
AKKARAJU SRINIVASDirectorJun 14Sale32.755,000163,75013,905Jun 17 07:28 PM
HIMES VAUGHN BEVP, Tech. Ops. & Proc. Sci.Jun 13Option Exercise9.2310,00092,30043,643Jun 17 07:26 PM
HIMES VAUGHN BEVP, Tech. Ops. & Proc. Sci.Jun 13Sale32.1110,000321,10033,643Jun 17 07:26 PM
SIEGALL CLAY BPresident and CEOJun 03Option Exercise10.332,00020,6601,079,211Jun 05 04:48 PM
SIEGALL CLAY BPresident and CEOJun 03Sale33.882,00067,7621,077,211Jun 05 04:48 PM
AKKARAJU SRINIVASDirectorMay 10Option Exercise12.7617,500223,30027,905May 14 09:30 AM
AKKARAJU SRINIVASDirectorMay 10Sale37.1717,500650,43010,405May 14 09:30 AM
SIEGALL CLAY BPresident and CEOMay 01Option Exercise10.332,00020,6601,079,211May 03 06:39 PM
SIEGALL CLAY BPresident and CEOMay 01Sale36.582,00073,1531,077,211May 03 06:39 PM
SIEGALL CLAY BPresident and CEOApr 01Option Exercise10.332,00020,6601,079,211Apr 03 06:31 PM
SIEGALL CLAY BPresident and CEOApr 01Sale35.532,00071,0621,077,211Apr 03 06:31 PM
BOERNER CHRISTOPHER S.SVP, CommercialMar 15Option Exercise15.108,500128,35042,253Mar 19 07:23 PM
BOERNER CHRISTOPHER S.SVP, CommercialMar 15Sale33.618,500285,66333,753Mar 19 07:23 PM
DOBMEIER ERICChief Operating OfficerMar 11Option Exercise12.1150,000605,671158,392Mar 12 07:10 PM
DOBMEIER ERICChief Operating OfficerMar 11Sale31.1660,0001,869,471112,948Mar 12 07:10 PM
SIMPSON TODD EChief Financial OfficerMar 07Option Exercise12.1220,176244,610133,451Mar 08 07:13 PM
SIMPSON TODD EChief Financial OfficerMar 07Sale30.7549,7181,528,706113,957Mar 08 07:13 PM
DOBMEIER ERICChief Operating OfficerMar 06Option Exercise12.0050,000600,000172,948Mar 06 07:16 PM
DOBMEIER ERICChief Operating OfficerMar 06Sale30.4250,0001,520,955122,948Mar 06 07:16 PM
DOBMEIER ERICChief Operating OfficerMar 05Option Exercise12.1612,567152,815135,515Mar 06 07:16 PM
SIEGALL CLAY BPresident and CEOMar 05Sale28.8768,7501,984,9501,077,211Mar 05 07:07 PM
DOBMEIER ERICChief Operating OfficerMar 05Sale28.9512,567363,815122,948Mar 06 07:16 PM
DOBMEIER ERICChief Operating OfficerMar 04Option Exercise12.1637,433455,185160,381Mar 06 07:16 PM
DOBMEIER ERICChief Operating OfficerMar 04Sale28.9537,4331,083,685122,948Mar 06 07:16 PM
SIEGALL CLAY BPresident and CEOMar 01Option Exercise10.332,00020,6601,172,961Mar 05 07:07 PM
SIEGALL CLAY BPresident and CEOMar 01Sale28.3027,000764,0671,145,961Mar 05 07:07 PM
GRYSKA DAVID WDirectorFeb 26Option Exercise6.6910,00066,90018,500Feb 27 04:40 PM
GRYSKA DAVID WDirectorFeb 25Sale27.1710,000271,7008,500Feb 27 04:40 PM
SIEGALL CLAY BPresident and CEOFeb 01Option Exercise10.332,00020,6601,172,961Feb 05 07:32 PM
SIEGALL CLAY BPresident and CEOFeb 01Sale29.612,00059,2161,170,961Feb 05 07:32 PM
Reynolds Thomas CChief Medical OfficerJan 28Option Exercise12.085,20762,90060,205Jan 29 08:16 PM
Reynolds Thomas CChief Medical OfficerJan 28Sale30.195,207157,18857,601Jan 29 08:16 PM
Reynolds Thomas CChief Medical OfficerJan 25Option Exercise15.462,08332,20359,684Jan 29 08:16 PM
Reynolds Thomas CChief Medical OfficerJan 25Sale29.842,08362,15557,601Jan 29 08:16 PM
Reynolds Thomas CChief Medical OfficerJan 15Option Exercise11.62125,0791,452,80493,094Jan 17 08:12 PM
Reynolds Thomas CChief Medical OfficerJan 15Sale28.00125,0793,502,52657,601Jan 17 08:12 PM
SIEGALL CLAY BPresident and CEOJan 04Option Exercise10.332,00020,6601,172,961Jan 04 06:46 PM
DOBMEIER ERICChief Operating OfficerJan 04Option Exercise11.0960,000665,400173,829Jan 04 06:49 PM
SIEGALL CLAY BPresident and CEOJan 04Sale25.052,00050,1041,170,961Jan 04 06:46 PM
DOBMEIER ERICChief Operating OfficerJan 04Sale24.9550,9831,272,026122,846Jan 04 06:49 PM
SIEGALL CLAY BPresident and CEOJan 02Option Exercise3.306,24920,6221,177,210Jan 04 06:46 PM
SIEGALL CLAY BPresident and CEOJan 02Sale23.836,249148,9391,170,961Jan 04 06:46 PM
DOBMEIER ERICChief Operating OfficerDec 17Option Exercise10.9262,418681,573163,829Dec 19 04:50 PM
DOBMEIER ERICChief Operating OfficerDec 17Sale23.7050,0001,184,955113,829Dec 19 04:50 PM
Reynolds Thomas CChief Medical OfficerDec 10Option Exercise10.946,58872,06162,939Dec 10 06:17 PM
Reynolds Thomas CChief Medical OfficerDec 10Sale25.756,588169,64157,601Dec 10 06:17 PM
Reynolds Thomas CChief Medical OfficerDec 07Option Exercise10.2930,000308,70087,601Dec 10 06:17 PM
Reynolds Thomas CChief Medical OfficerDec 07Sale25.7730,000773,08257,601Dec 10 06:17 PM
Reynolds Thomas CChief Medical OfficerDec 06Option Exercise12.1630,000364,80087,601Dec 10 06:17 PM
Reynolds Thomas CChief Medical OfficerDec 06Sale25.7730,000772,98357,601Dec 10 06:17 PM
LIPPMAN MARC EDirectorDec 05Option Exercise6.8367,500461,325132,950Dec 07 07:28 PM
Reynolds Thomas CChief Medical OfficerDec 05Option Exercise12.1610,000121,60067,601Dec 06 07:30 PM
LIPPMAN MARC EDirectorDec 05Sale25.5467,5001,723,950117,950Dec 07 07:28 PM
Reynolds Thomas CChief Medical OfficerDec 05Sale25.6010,000256,00057,601Dec 06 07:30 PM
Reynolds Thomas CChief Medical OfficerDec 04Option Exercise12.1130,000363,20067,601Dec 06 07:30 PM
Reynolds Thomas CChief Medical OfficerDec 04Sale25.5830,000767,50057,601Dec 06 07:30 PM
Reynolds Thomas CChief Medical OfficerDec 03Option Exercise12.1610,000121,60067,601Dec 03 07:48 PM
SIEGALL CLAY BPresident and CEODec 03Option Exercise3.308,25027,2251,179,211Dec 04 07:40 PM
WELCH DANIEL GDirectorDec 03Option Exercise8.383,11926,1376,119Dec 04 07:44 PM
SIEGALL CLAY BPresident and CEODec 03Sale25.198,250207,7771,170,961Dec 04 07:40 PM
Reynolds Thomas CChief Medical OfficerDec 03Sale25.4510,000254,50057,601Dec 03 07:48 PM
Reynolds Thomas CChief Medical OfficerNov 30Option Exercise12.0110,000120,08467,078Dec 03 07:48 PM
Reynolds Thomas CChief Medical OfficerNov 30Sale25.5010,000255,00057,601Dec 03 07:48 PM
Reynolds Thomas CChief Medical OfficerNov 29Option Exercise12.0020,000240,00067,601Dec 03 07:48 PM
Reynolds Thomas CChief Medical OfficerNov 29Sale25.3520,000507,08557,601Dec 03 07:48 PM
Reynolds Thomas CChief Medical OfficerNov 26Option Exercise12.003,00036,00060,601Nov 26 06:58 PM
Reynolds Thomas CChief Medical OfficerNov 26Sale25.503,00076,50057,601Nov 26 06:58 PM
Reynolds Thomas CChief Medical OfficerNov 23Option Exercise12.0017,000204,00067,601Nov 26 06:58 PM
Reynolds Thomas CChief Medical OfficerNov 23Sale25.3617,000431,10057,601Nov 26 06:58 PM
Reynolds Thomas CChief Medical OfficerNov 21Option Exercise15.4610,000154,60067,601Nov 26 06:58 PM
Reynolds Thomas CChief Medical OfficerNov 21Sale25.2510,000252,50057,601Nov 26 06:58 PM
Reynolds Thomas CChief Medical OfficerNov 20Option Exercise15.1710,000151,71466,767Nov 20 07:23 PM
Reynolds Thomas CChief Medical OfficerNov 20Sale25.0010,000250,00057,601Nov 20 07:23 PM
Reynolds Thomas CChief Medical OfficerNov 19Option Exercise15.4610,000154,60067,601Nov 20 07:23 PM
Reynolds Thomas CChief Medical OfficerNov 19Sale24.9010,000249,00257,601Nov 20 07:23 PM
DOBMEIER ERICChief Operating OfficerNov 13Option Exercise10.2924,811255,305126,222Nov 15 07:16 PM
DOBMEIER ERICChief Operating OfficerNov 13Sale23.5927,327644,724101,411Nov 15 07:16 PM
SIMPSON TODD EChief Financial OfficerNov 08Option Exercise5.2072,737378,412143,499Nov 09 06:03 PM
DOBMEIER ERICChief Operating OfficerNov 08Option Exercise6.4534,575223,107103,927Nov 09 06:01 PM
SIEGALL CLAY BPresident and CEONov 01Option Exercise5.008,25041,2851,177,211Nov 02 05:23 PM
SIEGALL CLAY BPresident and CEONov 01Sale25.518,250210,4761,170,961Nov 02 05:23 PM
DOBMEIER ERICChief Operating OfficerOct 15Option Exercise10.2925,000257,25094,352Oct 16 08:05 PM
DOBMEIER ERICChief Operating OfficerOct 15Sale25.0125,000625,29569,352Oct 16 08:05 PM
SIEGALL CLAY BPresident and CEOOct 01Option Exercise5.008,25041,2851,177,211Oct 02 08:23 PM
SIEGALL CLAY BPresident and CEOOct 01Sale26.598,250219,3441,170,961Oct 02 08:23 PM
HIMES VAUGHN BEVP, Tech. Ops. & Proc. Sci.Sep 10Option Exercise9.2310,00092,30043,643Sep 12 06:26 PM
HIMES VAUGHN BEVP, Tech. Ops. & Proc. Sci.Sep 10Sale28.7910,000287,90033,643Sep 12 06:26 PM
SIMPSON TODD EChief Financial OfficerSep 06Option Exercise12.1650,000608,000120,762Sep 07 07:40 PM
Reynolds Thomas CChief Medical OfficerSep 06Option Exercise8.2448,540399,970106,141Sep 10 08:02 PM
SIMPSON TODD EChief Financial OfficerSep 06Sale28.9750,0001,448,50070,762Sep 07 07:40 PM
Reynolds Thomas CChief Medical OfficerSep 06Sale29.7548,5401,444,06557,601Sep 10 08:02 PM
SIMPSON TODD EChief Financial OfficerSep 05Option Exercise11.1645,000502,073112,937Sep 07 07:40 PM
SIMPSON TODD EChief Financial OfficerSep 05Sale27.9745,0001,258,65070,762Sep 07 07:40 PM
SIEGALL CLAY BPresident and CEOSep 04Option Exercise5.008,25041,2851,177,211Sep 06 07:51 PM
SIEGALL CLAY BPresident and CEOSep 04Sale26.548,250218,9581,170,961Sep 06 07:51 PM
SIMPSON TODD EChief Financial OfficerAug 27Option Exercise10.6331,000329,49188,636Aug 27 07:55 PM
SIMPSON TODD EChief Financial OfficerAug 27Sale26.9731,000836,07070,762Aug 27 07:55 PM
SIMPSON TODD EChief Financial OfficerAug 24Option Exercise10.2914,000144,06084,762Aug 27 07:55 PM
SIMPSON TODD EChief Financial OfficerAug 24Sale26.9714,000377,58070,762Aug 27 07:55 PM
open in yahoo | open in reuters | open in google